MA54941A - Polythérapie pour le traitement de malignités des cellules b - Google Patents

Polythérapie pour le traitement de malignités des cellules b

Info

Publication number
MA54941A
MA54941A MA054941A MA54941A MA54941A MA 54941 A MA54941 A MA 54941A MA 054941 A MA054941 A MA 054941A MA 54941 A MA54941 A MA 54941A MA 54941 A MA54941 A MA 54941A
Authority
MA
Morocco
Prior art keywords
malignities
cell
treatment
multiple therapy
therapy
Prior art date
Application number
MA054941A
Other languages
English (en)
Inventor
Sriram Balasubramanian
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA54941A publication Critical patent/MA54941A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
MA054941A 2019-02-15 2020-02-14 Polythérapie pour le traitement de malignités des cellules b MA54941A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962806148P 2019-02-15 2019-02-15

Publications (1)

Publication Number Publication Date
MA54941A true MA54941A (fr) 2021-12-22

Family

ID=69740437

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054941A MA54941A (fr) 2019-02-15 2020-02-14 Polythérapie pour le traitement de malignités des cellules b

Country Status (15)

Country Link
US (1) US20200262925A1 (fr)
EP (1) EP3923945A1 (fr)
JP (1) JP2022520429A (fr)
KR (1) KR20210129111A (fr)
CN (1) CN113766918A (fr)
AU (1) AU2020222359A1 (fr)
BR (1) BR112021015964A2 (fr)
CA (1) CA3129593A1 (fr)
EA (1) EA202192256A1 (fr)
IL (1) IL285458A (fr)
JO (1) JOP20210225A1 (fr)
MA (1) MA54941A (fr)
MX (1) MX2021009821A (fr)
SG (1) SG11202108770TA (fr)
WO (1) WO2020165861A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150141971A (ko) * 2013-04-08 2015-12-21 파마싸이클릭스 엘엘씨 이브루티닙 병용 요법
JP6508785B2 (ja) * 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
LT3179992T (lt) * 2014-08-11 2022-06-27 Acerta Pharma B.V. Btk inhibitoriaus, pd-1 inhibitoriaus ir (arba) pd-l1 inhibitoriaus terapiniai deriniai
WO2016128912A1 (fr) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Combinaisons thérapeutiques d'un inhibiteur de btk, d'un inhibiteur de pi3k, d'un inhibiteur de jak-2, d'un inhibiteur de pd-1, et/ou d'un inhibiteur de pd-l1
US10736895B2 (en) * 2015-12-04 2020-08-11 Portola Pharmaceuticals, Inc. Cerdulatinib for treating hematological cancers
CN110087680B (zh) * 2016-08-19 2024-03-19 百济神州有限公司 使用包含btk抑制剂的组合产品治疗癌症

Also Published As

Publication number Publication date
KR20210129111A (ko) 2021-10-27
EP3923945A1 (fr) 2021-12-22
AU2020222359A1 (en) 2021-09-02
BR112021015964A2 (pt) 2021-10-05
WO2020165861A1 (fr) 2020-08-20
JP2022520429A (ja) 2022-03-30
CA3129593A1 (fr) 2020-08-20
IL285458A (en) 2021-09-30
JOP20210225A1 (ar) 2023-01-30
EA202192256A1 (ru) 2021-10-27
CN113766918A (zh) 2021-12-07
MX2021009821A (es) 2021-11-12
US20200262925A1 (en) 2020-08-20
SG11202108770TA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
GB201804514D0 (en) Treatment of pyroptosis
IL279260A (en) KDM1A inhibitors for the treatment of diseases
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA51738A (fr) Composés pour le traitement de la douleur
GB201902419D0 (en) Treatment of kidney injury
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
ZA201903795B (en) Treatment of water
GB201804515D0 (en) Treatment of necroptosis
IL281775A (en) Methods of treating infections using bacteria
GB201916428D0 (en) Treatment of hydro-carbon-contaminated materials
GB201805100D0 (en) Treatment of sarcopenic diseases
IL290880A (en) Treatment of symptoms induced by the menstrual cycle
MA54941A (fr) Polythérapie pour le traitement de malignités des cellules b
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA56179A (fr) Traitement de synucléinopathies
GB201907305D0 (en) Treatment of conditions
MA43801A (fr) Inhibiteurs des interactions des récepteurs de bêta-arrestine-neurokinine 1 pour le traitement de la douleur
MA54326A (fr) Compositions pour le traitement de la chute des cheveux
FR3036620B1 (fr) Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires
IL290983A (en) Treatment methods
MA55919A (fr) Composition pour le traitement des vertiges peripheriques